S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

SMMT Summit Therapeutics Inc

7.80

-0.07 (-0.89%)

29 Jun 2024 - Closed

Delayed by 15 minutes

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024

Click Here for more Summit Therapeutics Charts.

Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024

Click Here for more Summit Therapeutics Charts.

Summit Therapeutics Inc News

Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors
Friday 28 June 2024 (3 days ago) • Business Wire

Form D - Notice of Exempt Offering of Securities
Wednesday 19 June 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 18 June 2024 (2 weeks ago) • Edgar (US Regulatory)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Friday 14 June 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Monday 3 June 2024 (4 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Monday 3 June 2024 (4 weeks ago) • Edgar (US Regulatory)

Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
Monday 3 June 2024 (4 weeks ago) • Business Wire

Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
Saturday 1 June 2024 (4 weeks ago) • Business Wire

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
Saturday 1 June 2024 (1 month ago) • Business Wire

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Friday 31 May 2024 (1 month ago) • Business Wire

Form 8-K - Current report
Friday 31 May 2024 (1 month ago) • Edgar (US Regulatory)

Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
Friday 31 May 2024 (1 month ago) • Business Wire

More Summit Therapeutics Inc News Articles

Sterling vs AUD

Newcrest Mining

Woodside Petroleum

Gold vs US Dollar

Australia And New Zealan...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions